类风湿关节炎相关自身抗体检测的临床应用专家共识

2021-06-17 中国医师协会风湿免疫科医师分会 中华内科杂志.2021.60(6):516-521.

类风湿关节炎(RA)是一种常见的慢性、全身性自身免疫病,早期诊断、达标治疗是控制病情和改善预后的关键。RA患者可在血清中检测出类风湿因子和抗瓜氨酸化肽/蛋白抗体等多种自身抗体,其对RA早期诊断、鉴别诊

中文标题:

类风湿关节炎相关自身抗体检测的临床应用专家共识

发布日期:

2021-06-17

简要介绍:

类风湿关节炎(RA)是一种常见的慢性、全身性自身免疫病,早期诊断、达标治疗是控制病情和改善预后的关键。RA患者可在血清中检测出类风湿因子和抗瓜氨酸化肽/蛋白抗体等多种自身抗体,其对RA早期诊断、鉴别诊断、判断疾病的严重程度及预后评估等均有重要价值。RA相关自身抗体检测的标准化对其临床应用至关重要。中国医师协会风湿免疫科医师分会自身抗体检测专业委员会组织临床和实验室专家共同制定了本共识,旨在规范RA相关自身抗体的检测,为我国临床医生和检验人员正确应用、解读RA相关自身抗体提供参考。

相关资料下载:
[AttachmentFileName(sort=1, fileName=类风湿关节炎相关自身抗体检测的临床应用专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=4c9311c00212293b, title=类风湿关节炎相关自身抗体检测的临床应用专家共识, enTitle=, guiderFrom=中华内科杂志.2021.60(6):516-521., authorId=0, author=, summary=类风湿关节炎(RA)是一种常见的慢性、全身性自身免疫病,早期诊断、达标治疗是控制病情和改善预后的关键。RA患者可在血清中检测出类风湿因子和抗瓜氨酸化肽/蛋白抗体等多种自身抗体,其对RA早期诊断、鉴别诊, cover=https://img.medsci.cn/20211215/1639533528406_1614372.png, journalId=0, articlesId=null, associationId=1812, associationName=中国医师协会风湿免疫科医师分会, associationIntro= , copyright=0, guiderPublishedTime=Thu Jun 17 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>类风湿关节炎(RA)是一种常见的慢性、全身性自身免疫病,早期诊断、达标治疗是控制病情和改善预后的关键。RA患者可在血清中检测出类风湿因子和抗瓜氨酸化肽/蛋白抗体等多种自身抗体,其对RA早期诊断、鉴别诊断、判断疾病的严重程度及预后评估等均有重要价值。RA相关自身抗体检测的标准化对其临床应用至关重要。中国医师协会风湿免疫科医师分会自身抗体检测专业委员会组织临床和实验室专家共同制定了本共识,旨在规范RA相关自身抗体的检测,为我国临床医生和检验人员正确应用、解读RA相关自身抗体提供参考。</p> </div> </div> </div>, tagList=[TagDto(tagId=457, tagName=类风湿关节炎)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=457, guiderKeyword=类风湿关节炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8675, appHits=484, showAppHits=0, pcHits=1240, showPcHits=8191, likes=2, shares=52, comments=22, approvalStatus=1, publishedTime=Wed Jun 30 23:55:06 CST 2021, publishedTimeString=2021-06-17, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=qiushida2, createdTime=Wed Jun 30 23:29:42 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 12:16:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=类风湿关节炎相关自身抗体检测的临床应用专家共识.pdf)])
类风湿关节炎相关自身抗体检测的临床应用专家共识.pdf
下载请点击:
评论区 (21)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2111954, encodeId=9d0621119543e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3b8129338, createdName=ms5000000725120296, createdTime=Sun Jan 29 09:46:19 CST 2023, time=2023-01-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1226403, encodeId=87f81226403f8, content=很好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c061838963, createdName=ms6029778864262419, createdTime=Tue Jun 14 15:44:46 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213384, encodeId=6f2a121338477, content=很实用,***!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9e05316193, createdName=1489a9d6m69暂无昵称, createdTime=Fri Apr 22 10:45:53 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208633, encodeId=1d4d12086330d, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33d11836786, createdName=孙红丽, createdTime=Mon Apr 04 20:38:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201066, encodeId=75f9120106605, content=不错 实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:10:29 CST 2022, time=2022-03-09, status=1, ipAttribution=)]
    2023-01-29 ms5000000725120296 来自湖北省

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2111954, encodeId=9d0621119543e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3b8129338, createdName=ms5000000725120296, createdTime=Sun Jan 29 09:46:19 CST 2023, time=2023-01-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1226403, encodeId=87f81226403f8, content=很好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c061838963, createdName=ms6029778864262419, createdTime=Tue Jun 14 15:44:46 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213384, encodeId=6f2a121338477, content=很实用,***!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9e05316193, createdName=1489a9d6m69暂无昵称, createdTime=Fri Apr 22 10:45:53 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208633, encodeId=1d4d12086330d, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33d11836786, createdName=孙红丽, createdTime=Mon Apr 04 20:38:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201066, encodeId=75f9120106605, content=不错 实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:10:29 CST 2022, time=2022-03-09, status=1, ipAttribution=)]
    2022-06-14 ms6029778864262419

    很好用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2111954, encodeId=9d0621119543e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3b8129338, createdName=ms5000000725120296, createdTime=Sun Jan 29 09:46:19 CST 2023, time=2023-01-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1226403, encodeId=87f81226403f8, content=很好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c061838963, createdName=ms6029778864262419, createdTime=Tue Jun 14 15:44:46 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213384, encodeId=6f2a121338477, content=很实用,***!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9e05316193, createdName=1489a9d6m69暂无昵称, createdTime=Fri Apr 22 10:45:53 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208633, encodeId=1d4d12086330d, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33d11836786, createdName=孙红丽, createdTime=Mon Apr 04 20:38:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201066, encodeId=75f9120106605, content=不错 实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:10:29 CST 2022, time=2022-03-09, status=1, ipAttribution=)]
    2022-04-22 1489a9d6m69暂无昵称

    很实用,***!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2111954, encodeId=9d0621119543e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3b8129338, createdName=ms5000000725120296, createdTime=Sun Jan 29 09:46:19 CST 2023, time=2023-01-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1226403, encodeId=87f81226403f8, content=很好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c061838963, createdName=ms6029778864262419, createdTime=Tue Jun 14 15:44:46 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213384, encodeId=6f2a121338477, content=很实用,***!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9e05316193, createdName=1489a9d6m69暂无昵称, createdTime=Fri Apr 22 10:45:53 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208633, encodeId=1d4d12086330d, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33d11836786, createdName=孙红丽, createdTime=Mon Apr 04 20:38:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201066, encodeId=75f9120106605, content=不错 实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:10:29 CST 2022, time=2022-03-09, status=1, ipAttribution=)]
    2022-04-04 孙红丽

    谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2111954, encodeId=9d0621119543e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3b8129338, createdName=ms5000000725120296, createdTime=Sun Jan 29 09:46:19 CST 2023, time=2023-01-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1226403, encodeId=87f81226403f8, content=很好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c061838963, createdName=ms6029778864262419, createdTime=Tue Jun 14 15:44:46 CST 2022, time=2022-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213384, encodeId=6f2a121338477, content=很实用,***!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9e05316193, createdName=1489a9d6m69暂无昵称, createdTime=Fri Apr 22 10:45:53 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208633, encodeId=1d4d12086330d, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33d11836786, createdName=孙红丽, createdTime=Mon Apr 04 20:38:32 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201066, encodeId=75f9120106605, content=不错 实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:10:29 CST 2022, time=2022-03-09, status=1, ipAttribution=)]
    2022-03-09 ms9000001115066421

    不错 实用

    0

拓展阅读

2010 BSR/BHPR 类风湿关节炎中抗肿瘤坏死因子疗法的安全指引

英国风湿病学会(BSR,British Society for Rheumatology) · 2010-01-01

2010版类风湿关节炎诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-04-01

2010 依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议

中国风湿免疫科相关专家小组(统称) · 2010-06-30

2010 ACR/EULAR 类风湿关节炎分类标准

美国风湿病学会(ACR,American College of Rheumatology) · 2010-09-01

2011 BSR/BHPR 指南:使用利妥昔单抗治疗类风湿关节炎

英国风湿病学会(BSR,British Society for Rheumatology) · 2011-01-01

2011SIGN 苏格兰国家类风湿关节炎早期治疗临床指南

苏格兰校际指南网络(SIGN,Scottish Intercollegiate Guidelines Network) · 2011-01-01